The monoclonal antibody-based ADCs, including the anti-CD33 drug gemtuzumab ozogamicin, the first ADC authorized by the FDA, and the anti-HER2 drug adotrastuzumab emtansine to treat advanced breast carcinoma, have achieved a significant progress (220). This evidence concerns the gene ERBB2 and breast carcinoma.